Technology areas: Biotechnology & Pharmaceuticals • Semiconductors, Circuits & Optics
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Stichting VU currently manages 3 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are spread across 3 distinct examiners and 3 distinct art units, indicating a high level of diversification in the examination of the organization's patent applications. This suggests that the research and development efforts in this sector cover a wide range of distinct technical topics within the biotech field.
The busiest examiner for the organization is SEAMAN, D MARGARET M, who is assigned 1 pending office action. With a busiest examiner pending count of 1 and a total of 3 pending office actions, the workload is perfectly distributed among the 3 distinct examiners. This structure ensures that no single examiner has a dominant influence over the current patent pipeline, allowing for a variety of perspectives from different USPTO officials.
Practitioners should observe that managing 3 pending office actions across 3 distinct art units requires a broad and adaptable prosecution strategy. Each matter must be handled according to the specific requirements of its respective art unit and examiner. The focus on Biotechnology & Pharmaceuticals provides a general framework, but the administrative and substantive challenges are likely to be unique for each of the three active files.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (33%) |
| §103 only | 1 (33%) |
| §112 only | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SEAMAN, D MARGARET M | 1 | 76.6% | +8.1% |
| BAUSCH, SARAE L | 1 | 29.7% | +45.0% |
| NGUYEN, KEMAYA DEANN HUU | 1 | 74.4% | +38.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18254732 | PERSONALIZED TUMOR MARKERS | BAUSCH, SARAE L | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18023172 | SPECTROSCOPY APPARATUS | NGUYEN, KEMAYA DEANN HUU | 73d overdue |
| 18254732 | PERSONALIZED TUMOR MARKERS | BAUSCH, SARAE L | — |
| Art Unit | Apps |
|---|---|
| 1625 | 1 |
| 1699 | 1 |
| 2877 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18843308 | MODULATORS OF ACKR3 AND USES THEREOF | SEAMAN, D MARGARET M | 1625 | §112 | Non-Final OA | — | Pending | Sep 03, 2024 |
| 18254732 | PERSONALIZED TUMOR MARKERS | BAUSCH, SARAE L | 1699 | §101§102§112 | Non-Final OA | — | Pending | May 26, 2023 |
| 18023172 | SPECTROSCOPY APPARATUS | NGUYEN, KEMAYA DEANN HUU | 2877 | §103 | Final Rejection | 73d overdue | Pending | Feb 24, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialStichting VU has 3 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
D Margaret M Seaman has the most, with 1 of Stichting VU's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
